Safety Reading Notes

Read safety context beside the research guide.

The Oleamide source set includes safety-context rows around oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 12432941

Mechanistic research summary: insufficient (9), mechanistic or pharmacological (4)

PubMed For Dummies Article

Oleamide Evidence Review: the long-form source walk-through

Quick read
  • Oleamide currently has 13 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 12432941
  • The evidence classes most visible in the row language are insufficient (9), and mechanistic or pharmacological (4). PMID 11945157
  • The study-design language most visible in the row language is Narrative or expert review (8), and Animal study (4). PMID 14691053
  • The repeated topics are oleamide biology, sleep-related physiology, receptor pharmacology, metabolism... (13), which tells the reader where to start opening PubMed and DOI links. PMID 17445087

Start with the research question

Oleamide is built from 13 source-backed evidence row(s) and 13 research source(s). The current evidence classes read as insufficient (9), and mechanistic or pharmacological (4), and the study-design language most often reads as Narrative or expert review (8), and Animal study (4). PMID 12432941

The row-level question is not simply whether Oleamide is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are oleamide biology, sleep-related physiology, receptor pharmacology, metabolism... (13). PMID 12432941

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 10469890

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 18514375

Mechanistic evidence 4 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 9344854

Limits and uncertainty 9 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 12505696

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 10197045

Where this page has the most source density

The largest bucket surfaced for this page is oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is the next evidence bucket, which gives readers another way to see what the literature repeatedly circles. PMID 12432941

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 12432941

Bucket chapters: what the literature is circling

oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms

13 research sources 13 rows (1119-1202) Mechanistic research summary: insufficient (9), mechanistic or pharmacological (4)

Oleamide appears in rows studying oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms. It currently draws from 13 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 12432941

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 12432941

  • Evidence row 1119

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; stu... PMID 12432941

  • Evidence row 1202

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (outcome measure: oleamide biology, sleep-related physiology, recep... PMID 33537938

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (4 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 12432941

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 12432941

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 10221757
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 8900284
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 10574567

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 12432941

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 12432941

Source-reading checklist for Oleamide

  1. Open the linked PubMed or DOI record. PMID 33537938
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 12432941
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 11945157
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 14691053
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 17445087

Source Notes

Oleamide source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1119

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 12432941

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoid hydrolases.
  2. Evidence row 1120

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 11945157

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications.
  3. Evidence row 1121

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 14691053

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Oleamide: a member of the endocannabinoid family?
  4. Evidence row 1122

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 17445087

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Oleamide: a fatty acid amide signaling molecule in the cardiovascular system?
  5. Evidence row 1123

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 10469890

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?
  6. Evidence row 1124

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 18514375

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of the CB1 receptor in the regulation of sleep.
  7. Evidence row 1125

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 9344854

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The sleep inducing factor oleamide is produced by mouse neuroblastoma cells.
  8. Evidence row 1126

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 12505696

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The enzymatic inactivation of the fatty acid amide class of signaling lipids.
  9. Evidence row 1127

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 10197045

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules.
  10. Evidence row 1128

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 10221757

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors.
  11. Evidence row 1129

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 8900284

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides.
  12. Evidence row 1130

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 10574567

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist.
  13. Evidence row 1202

    Oleamide studied for oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms; evidence class: insufficient (outcome measure: oleamide biology, sleep-related physiology, receptor pharmacology, metabolism, or safety-relevant mechanisms). PMID 33537938

    Evidence class: insufficient. Source: Cannabinoids and Sleep/Wake Control.